ravive, Inc. (NASDAQ:ARAV, ", the Company", ))))), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced the presentation of updated results from its ongoing Phase 1b/2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place February 16-18, 2023 in San Francisco and virtually. The poster presentation will highlight updated results from the Phase 1b portion of the trial in 26 patients with advanced or metastatic ccRCC who have progressed after 1 or 2 prior lines of immuno-oncology (IO)- and vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI)-based therapies.
Blink Charging Names Ritsaart Van Montfrans Chairman Of Board Of Directors
Blink Charging Co. (NASDAQ:BLNK) ("Blink" or the "Company"), a leading manufacturer, owner and operator of electric vehicle (EV) charging equipment and services, announced today that its Board of
